Musi wa9 Chivabvu, 2025, Hansoh Pharmaceutical yakazivisa kuti chiratidzo chitsva cheAmeile (mapiritsi ealmonertinib mesylate) chabvumidzwa kutengeswa. Chiratidzo chitsva ndechekurapa varwere vakuru vane kenza yemapapu isiri diki (NSCLC) vane bundu rine epidermal growth factor receptor (EGFR) exon 19 deletion kana exon 21 (L858R) mutations, uye vakabviswa bundu. Ameile ikozvino ine zviratidzo zvina zvakatenderwa muChina, ichiramba iri pamberi pakati peEGFR-TKIs yechizvarwa chechitatu yakagadzirwa munyika.
Kubvumidzwa uku kwakavakirwa zvakanyanya pakudzidza kweARTS (HS-10296-302), bvunzo yekiriniki yePhase III yakasarudzika, isina kupofumadzwa kaviri, inodzorwa, ine nzvimbo dzakawanda. Mhedzisiro yekudzidza iyi yakapihwa semushumo wemuromo paMusangano weGore weAmerican Association for Cancer Research (AACR) we2025.
Ruzivo kubva muchidzidzo cheARTS chakapihwa paMusangano weGore negore weAACR wa2025 rwakasimbisa kuti kune varwere vakabviswa zvachose EGFR-mutant NSCLC yedanho rechipiri kusvika rechitatuB, kurapwa kwekuwedzera neAmeile—kana zvichibvira—kunogona kuvandudza zvikuru kupona kusina chirwere (DFS). Chiyero cheDFS chemakore maviri chakasvika 90.2%, neHR ye0.17, uye kuchengetedzeka kwese kwaive kwakajairika. Zvakakosha kuti chidzidzo ichi chakanyoresa varwere vekuChina chete, zvichiratidza kushanda kwakakosha uye kuchengetedzeka kwakarongeka kweEGFR-TKI yakagadzirwa munyika muvanhu vekuChina.
Nezve Ameile
Semushonga wekutanga wechizvarwa chechitatu cheEGFR-TKI muChina, Ameile (Aumolertinib Mesilate Tablets) ine mafuta akanaka uye kugadzikana, zvichiita kuti ipinde zviri nani muropa-uropi nekuwanda kwezviitiko zvisingafadzi. Parizvino, Ameile yatenderwa zviratidzo zvina: kurapwa kwechipiri kwevarwere vane NSCLC yepamusoro kana metastatic munharaunda vane T790M mutation, avo vakafambira mberi mushure mekurapwa kweEGFR-TKI kana mushure mayo; kurapwa kwekutanga kwevarwere vakuru vane NSCLC yepamusoro kana metastatic munharaunda vane mabundu ane EGFR exon 19 deletions kana exon 21 (L858R) substitute mutation positive; kurapwa kwevarwere vane kenza yemapapu isina kubviswa (Stage III) non-small cell lung cancer ("NSCLC") vane chirwere chisina kufambira mberi mushure mekurapa kwechokwadi kwe platinum-based chemoradiotherapy vane mabundu ane epidermal growth factor receptor ("EGFR") exon 19 deletions kana exon 21 (L858R) substitute mutations; kurapwa kwekubatsira varwere vakuru vane kenza yemapapu isiri diki (NSCLC) vane bundu rine epidermal growth factor receptor (EGFR) exon 19 deletion kana exon 21 (L858R) mutations, uye vakabviswa bundu resection.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Email：myimmnet@163.com
Nguva yekutumira: Chivabvu-13-2025